Cefiderocol: A Siderophore Cephalosporin.

Published in: The Annals of pharmacotherapy (2020)

Cefiderocol shows promising activity against MDR Gram-negative pathogens. Its use in the treatment of serious infections caused by CR Gram-negative bacteria needs further evaluation in phase III clinical studies.

Keyphrases

gram negative
multidrug resistant
phase iii
open label
clinical trial
double blind
placebo controlled
randomized controlled trial
combination therapy
study protocol